ReviewFoods (Basel, Switzerland)2024
Probiotics and Non-Alcoholic Fatty Liver Disease: Unveiling the Mechanisms of
Review in Foods (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Probiotics as emerging adjuncts in metabolic associated fatty liver disease therapy-a systemic review.BMC gastroenterology · 2026Pooled it
- Probiotics in Cardiometabolic Diseases: Current Evidence, Postbiotic Perspectives, and Future Directions.Journal of microbiology and biotechnology · 2026Review
- Strain-Specific Effects of three Different Native Lactobacillus on Anthropometric Indices, Appetite, and Nesfatin-1 in Obese Adults: A Triple-Blind Randomized Clinical Trial.Probiotics and antimicrobial proteins · 2026Article
- Synthesis and application of encapsulated Bifidobacterium Longum for mitigation of liver fibrosis via modulation of oxidative stress and inflammation in BDL rat model.World journal of microbiology & biotechnology · 2026Article
- The role of Traditional Chinese Medicine in the management of liver disease: targeting gut microbiome.Chinese medicine · 2026Review
- BPA Disrupts Hepatic Lipid and Carbohydrate Metabolism in Female Zebrafish: Protective Effects of Probiotics Revealed by FTIRI and Lipidomics.International journal of molecular sciences · 2026Article
- Article
- Obesity is the culprit behind fatty acid-induced inflammation.Nutrition & metabolism · 2026Review
- Functional metagenomic reconstruction of microbial pathways altered by probiotic supplementation in liver failure.Frontiers in cellular and infection microbiology · 2026Article
- Interplay between circadian rhythms, gut microbiota, and MASLD: from mechanistic foundations to therapeutic opportunities.Frontiers in medicine · 2026Review
- Microbiota-derived indole-3-acetic acid alleviates rumen epithelial barrier dysfunction during the peripartum period through AhR signaling.NPJ biofilms and microbiomes · 2025Article
- Clinical and biological significance of the relationship between gut microbiota and liver disease.World journal of hepatology · 2025Review
- Intestinal congestion-driven gut dysbiosis: a cross-disease hemodynamic mechanism in liver cirrhosis and heart failure.Journal of translational medicine · 2025Article
- Serum Metabolomics Uncovers Immune and Lipid Pathway Alterations in Lambs Supplemented with Novel LAB-International journal of molecular sciences · 2025Article
- The current findings on the gut-liver axis and the molecular basis of NAFLD/NASH associated with gut microbiome dysbiosis.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Toxins to treatments: Impact of environmental pollutants, gut microbiota, and natural compounds on non-alcoholic fatty liver disease progression.World journal of hepatology · 2025Review
- Heat-InactivatedFoods (Basel, Switzerland) · 2025Article
- Liver immunology: Biological role and clinical significance.World journal of hepatology · 2025Review
- Article
- Yogurt in Combination with InactivatedAnimals : an open access journal from MDPI · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
In recent years, the prevalence of non-alcoholic fatty liver disease (NAFLD) has risen annually, yet due to the intricacies of its pathogenesis and therapeutic challenges, there remains no definitive medication for this condition. This review explores the intricate relationship between the intestinal microbiome and the pathogenesis of NAFLD, emphasizing the substantial roles played by
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.